Metropolitan Hospital

At Metropolitan Hospital, the 2nd Oncology Clinic is conducting a large share of its studies in neoplasms, with a strong focus on non-small cell lung cancer, small cell lung cancer, and other advanced solid tumors. These trials are mainly designed to test new treatment options, compare them with current standards, and improve outcomes for people with hard-to-treat cancers.

• Advanced non-small cell lung cancer, including biomarker-defined subtypes such as KRAS G12C, EGFR, ROS1, and c-Met alterations
• Small cell lung cancer and limited-stage disease, with studies exploring better survival and disease control
• New immunotherapy and antibody-drug conjugate combinations aimed at improving progression-free survival and overall survival

Much of the research also examines treatment strategies after surgery or chemoradiation, reflecting a broader effort to refine care for patients with lung cancer at different stages of disease.

The site is active in melanoma research, especially for patients with resected or advanced disease. These trials are focused on preventing recurrence, strengthening immune-based treatment approaches, and evaluating whether newer combinations can outperform established therapies.

• Completely resected melanoma, where studies aim to reduce the risk of return after surgery
• Advanced and resectable melanoma, including peri-operative and adjuvant treatment strategies
• Immunotherapy combinations designed to improve recurrence-free survival and deepen treatment response

These trials reflect a strong interest in helping patients stay disease-free longer while expanding the role of immune-based cancer treatment.

Research at this Athens site also includes several studies in breast cancer, ranging from early-stage disease to advanced and metastatic forms. The main goal is to improve treatment effectiveness, support older or higher-risk patients, and explore whether biomarker-guided care can better match therapy to the disease.

• Early-stage and high-risk breast cancer, including hormone receptor-positive and HER2-negative disease
• Advanced breast cancer, including triple-negative and ESR1-mutated disease
• Trials evaluating treatment optimization, recurrence prevention, and the use of ctDNA to help track residual disease

The Metropolitan Hospital program in this area is especially notable for studies that aim to personalize care and improve tolerance in vulnerable patient groups.

Beyond oncology, the site is involved in cardiovascular diseases and nervous system diseases, with trials focused on reducing the risk of stroke and managing long-term vascular conditions. These studies are intended to improve prevention, safety, and everyday treatment for patients with common but serious cardiovascular problems.

• Acute ischemic stroke and prevention after stroke or high-risk transient ischemic attack
• Arterial hypertension, with research on better blood pressure control
• Familial hypercholesterolemia and elevated cardiovascular risk, with an emphasis on long-term management

This mix of studies shows a broader clinical research profile that extends into vascular prevention and chronic disease care.

The 2nd Oncology Clinic is also studying a range of other cancers, including digestive system, kidney, urinary tract, and prostate malignancies. These trials are generally designed to test newer therapies, compare them against standard treatment, and improve control of advanced disease.

• Gastric, esophageal, colorectal, and endometrial cancer
• Renal cell carcinoma, urothelial carcinoma, and prostate cancer, including metastatic and castration-resistant disease
• Studies in solid tumors that look for broader treatment activity across multiple cancer types

Overall, the research portfolio combines disease-specific trials with broader oncology programs aimed at expanding treatment options for patients with advanced cancers.